On May 23, PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation, announced that the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) have been updated to include BESREMi®(ropeginterferon alfa-2b-njft) as a preferred therapeutic option for the treatment of adults with both high and low-risk polycythemia vera, regardless of treatment history.
For more information read the PharmaEssentia announcement.
Posted 6/8/2023
